Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat in Pediatric Patients With Sickle Cell Disease
NCT06198712Phase 2Recruiting
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Jan 2023
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of etavopivat in sickle cell disease (SCD), sponsored by Forma Therapeutics, Inc.. Started Jan 2023; status: recruiting.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06198712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06198712.